Prosecution Insights
Last updated: September 17, 2026
Application No. 18/702,334

CHIP-BASED CARTRIDGE FOR BIOLOGICAL DETECTION AND USES THEREOF

Non-Final OA §112
Filed
Apr 18, 2024
Priority
Oct 18, 2021 — nonprovisional of PCTUS2021055339 +1 more
Examiner
CHIN, CHRISTOPHER L
Art Unit
Tech Center
Assignee
Erick Wang
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
1y 3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
576 granted / 713 resolved
+20.8% vs TC avg
Strong +23% interview lift
Without
With
+22.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
22 currently pending
Career history
731
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
27.5%
-12.5% vs TC avg
§102
17.6%
-22.4% vs TC avg
§112
36.9%
-3.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 713 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 is vague. In line 3, the recitation of “the part” lacks antecedent support. In line 12, the recitation of “the reaction” lacks antecedent support. Claim 6 is vague as to what comprises a “function protein” vs a non-functional protein. The metes and bounds of what is encompassed by “functional protein” is not clear. Claims 9 and 13 are vague. In line 1 of each claim, the phrase “the washing step, the washing” is not clear. Claims 10 and 14 are vague. In line 1 of each claim, the phrase “the detection step, the detection” is not clear. Claim 11 is vague. In line 12, the recitation of “quickly” is a relative term. It is not clear as to what time frame is considered “quickly”. Allowable Subject Matter Claims 1-18 are free of the prior art of record. The closest prior art is Nakatani (US 2021/0302350 A1) which discloses a biosensor comprising a substrate (10) that supports counter electrode (11) and working electrode (12). Working electrode (12) has a region (13) and supports receptor for binding a detection target. Receptor region (13) is aligned below an opening (18) in flow guiding layer (16). A spacer layer (15) has a sample supply port (17) which carries sample by capillary action toward opening (18) to drop directly onto receptor region (13) ([0060] and [0099]). However, opening (18) is not for direct application of sample to region (13) which contains receptor for binding to a target. Sample enters the biosensor by supply port (17) and flows to region (13) by capillary action. Opening (18) functions as a venting hole to facilitate the capillary action that brings sample in from supply port (17) and does not form a microfluidic channel to region (13). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER L CHIN whose telephone number is (571)272-0815. The examiner can normally be reached Monday - Friday, 10:00am - 6:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bao-Thuy Nguyen can be reached at 571-272-0824. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHRISTOPHER L CHIN/Primary Examiner, Art Unit 1677 8/21/2026
Read full office action

Prosecution Timeline

Apr 18, 2024
Application Filed
Aug 26, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12698518
PROCESS OF DIRECTLY DETECTING AND IDENTIFYING A MICROORGANISM IN A BIOLOGICAL SAMPLE DILUTED IN AN ENRICHMENT BROTH
5y 7m to grant Granted Aug 04, 2026
Patent 12699086
MODIFIED ELISA WITH HEMOGLOBIN CORRECTION APPARATUS AND METHODS THEREOF
3y 3m to grant Granted Aug 04, 2026
Patent 12693221
AUTOMATED IMMUNOANALYZER SYSTEM FOR PERFORMING DIAGNOSTIC ASSAYS FOR AUTOIMMUNE AND INFECTIOUS DISEASES
6y 0m to grant Granted Jul 28, 2026
Patent 12693291
METHODS AND DEVICES FOR USING MUCOLYTIC AGENTS INCLUDING N-ACETYL CYSTEINE (NAC)
5y 3m to grant Granted Jul 28, 2026
Patent 12687495
SINGLE CELL SELECTION AND ISOLATION
5y 0m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
99%
With Interview (+22.8%)
3y 8m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 713 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month